DEVLO SRL

Devlo SRL is an Italian company operating in the biopharmaceutical sector, with a focus on inflammation and immunology therapeutics.

Reviewed by 7wData
Share Email

On this page

Profile

Develops immunology therapeutics and provides contract drug manufacturing services for biotech companies.

Devlo SRL is an Italian company operating in the biopharmaceutical sector, with a focus on inflammation and immunology therapeutics. The company has developed a dual business model combining therapeutic innovation with revenue-generating drug development and manufacturing services through its CDMO (Contract Development and Manufacturing Organization) unit, Scinai Bioservices. Founded to address gaps in local biopharma infrastructure, Devlo has positioned itself as a boutique CDMO serving early-stage biotech companies in Israel, the U.S., and Europe.

In 2025, the company reported CDMO revenues of $1.3 million, doubling year-over-year, while maintaining a lean operational structure with R&D expenses reduced to $2.4 million. Post-2025, Devlo expanded its capabilities through the acquisition of Recipharm Israel's manufacturing site, enhancing its small-molecule and biologics production capacity. The company is also advancing its proprietary NanoAbs platform, focusing on IL-17-based therapies for inflammatory diseases, with grant applications pending for non-dilutive funding. Financial resilience remains a challenge, with a net loss of $8.3 million in 2025, though strategic collaborations and grant funding aim to offset capital needs.

Track DEVLO SRL and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Early-stage biotech firms needing GMP manufacturing
  • Pharmaceutical companies seeking immunology therapeutics
  • Research institutions collaborating on IL-17-based therapies
  • Government and EU grant programs funding biopharma innovation

Strengths and what to watch

Strengths

  • Dual revenue stream from CDMO services and proprietary R&D
  • Strategic collaboration with Recipharm expanding manufacturing capabilities
  • Non-dilutive grant funding strategy reducing reliance on equity financing

Watch for

  • Net losses persist ($8.3M in 2025) despite revenue growth
  • Dependence on pending EU grant approvals for pipeline funding
  • Integration risks post-Recipharm acquisition impacting CDMO operations

Key Information

Founded
1993
Headquarters
Vle Dell Oceano

Frequently Asked Questions

What does DEVLO SRL do in biopharma?

DEVLO SRL develops immunology therapeutics while operating a CDMO unit for biotech firms. The Italian company combines proprietary drug development (focusing on IL-17-based NanoAbs) with contract manufacturing services. Its 2025 acquisition of Recipharm's site expanded small-molecule and biologics production capacity.

How does DEVLO SRL make money?

DEVLO generates revenue through CDMO services ($1.3M in 2025) and therapeutic R&D. Its boutique manufacturing serves early-stage biotechs, while the NanoAbs platform targets inflammatory diseases. The company pursues EU grants to offset $8.3M losses, reducing reliance on equity financing.

What is DEVLO's NanoAbs platform?

DEVLO's proprietary NanoAbs platform focuses on IL-17-based therapies for inflammatory diseases. This R&D arm complements their CDMO business, with pending grant applications for non-dilutive funding. The approach aims to address gaps in immunology treatment pipelines.

Can small biotechs use DEVLO's manufacturing?

Yes, DEVLO's CDMO unit specializes in GMP manufacturing for early-stage biotech companies across Israel, the U.S., and Europe. Their Recipharm-acquired facility enhances small-molecule and biologics production capacity, serving clients needing scalable contract services.

Is DEVLO SRL financially stable?

DEVLO reported $8.3M net losses in 2025 despite CDMO revenue doubling to $1.3M. Strategic collaborations (like Recipharm) and EU grant applications aim to improve stability. The lean operational structure keeps R&D expenses at $2.4M annually.

How does DEVLO fund its research?

DEVLO prioritizes non-dilutive grants over equity financing for its NanoAbs platform. Pending EU applications could fund IL-17 therapy development. The CDMO division's growth ($1.3M revenue) also cross-subsidizes R&D, though $8.3M losses persist.

Sources

  1. www.prnewswire.com — 2025 financial results and Recipharm collaboration
  2. www.prnewswire.com — Nine-month 2025 financials and CDMO growth
  3. www.reuters.com — Market context for biopharma sector
  4. www.reuters.com — Financial and strategic comparisons in biopharma